Fake job recruiters hide malware in developer coding challenges

A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...
North Penn Now

Machine Learning Using Python: A Complete Learning Path With Practical Projects

Machine learning is an essential component of artificial intelligence. Whether it’s powering recommendation engines, fraud detection systems, self-driving cars, generative AI, or any of the countless ...
Dot Physics on MSN

Creating a Python simulation of a tipping stick

Learn how to create a Python simulation of a tipping stick! In this video, we guide you step by step through coding a physics-based simulation that models tipping motion, friction, and torque. Perfect ...

So yeah, I vibe-coded a log colorizer—and I feel good about it

Oh, sure, I can “code.” That is, I can flail my way through a block of (relatively simple) pseudocode and follow the flow. I ...
Benzinga.com

Here's Why Replimune Group (REPL) Stock Is Up Over 100% Today

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Yahoo Finance

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune Group’s REPL share price tumbled 54.2% over the past three months. The massive setback was observed after the FDA issued a complete response letter (CRL) in July, against the biologics ...
Yahoo Finance

Replimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit Announcements

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...
Seeking Alpha

Replimune rebounds despite analyst downgrades on FDA rejection

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...
Business Wire

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
Seeking Alpha

Replimune plunges as FDA rejects its lead drug for skin cancer

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...
Benzinga.com

FDA Rejects Replimune's Skin Cancer Drug, Stock Sinks (CORRECTED)

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...